I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab , a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics,... | May 31, 2022
Source: marketscreener.com